Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03873883 · ClinicalTrials.gov registry record · Phase 1
First-in-Human Study of EOS100850 (Inupadenant) in Patients with Cancer
A Phase 1 study, sponsored by iTeos Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 119
- Enrollment target
NCT03873883 is a Phase 1 study that has completed, run by iTeos Therapeutics. The registered enrollment target is 119 participants.
The verdict
NCT03873883, a Phase 1 study, has completed, sponsored by iTeos Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 119 participants
- Enrollment target
Study Summary
Multicenter, open-label, dose-escalation Phase I/Ib clinical study to evaluate the safety and tolerability, the MTD/RP2D, pharmacokinetics (PK), pharmacodynamics (PD), and antitumor activity of EOS100850 (Inupadenant) as a Single Agent and in Combination with Pembrolizumab and/or Chemotherapy in Participants with Advanced Cancers.
Interventions
- DRUG Pembrolizumab
- DRUG Chemotherapy
- DRUG EOS100850
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 119 participants |
| Start Date | 2019-02-05 |
| Est. Completion | 2024-05-28 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03873883
The ClinicalTrials.gov registry entry for NCT03873883 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 119 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is iTeos Therapeutics, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Pembrolizumab is the first listed.
NCT03873883 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03873883 about?
NCT03873883 is a clinical study titled "First-in-Human Study of EOS100850 (Inupadenant) in Patients with Cancer". Multicenter, open-label, dose-escalation Phase I/Ib clinical study to evaluate the safety and tolerability, the MTD/RP2D, pharmacokinetics (PK), pharmacodynamics (PD), and antitumor activity of EOS100850 (Inupadenant) as a Single Agent and in Combination with Pembrolizumab and/or Chemotherapy in Par...
What is the current status of trial NCT03873883?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 119 participants. The study started on 2019-02-05. Estimated completion is 2024-05-28.
What interventions are being tested in trial NCT03873883?
The interventions under investigation include: Pembrolizumab (DRUG), Chemotherapy (DRUG), EOS100850 (DRUG).
Who is sponsoring clinical trial NCT03873883?
This trial is sponsored by iTeos Therapeutics, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.